T0	Participants 45 60	prostate cancer
T1	Participants 128 165	follow-up of 212 randomized patients.
T2	Participants 167 246	Two hundred and twelve patients treated for prostatic cancer grade I or II were
T3	Participants 294 494	The patients were part of a multicentre study in the Stockholm area and had been randomized to treatment with either estramustine phosphate (Estracyt) or polyestradiol phosphate and ethinyl estradiol.